Skip to content
Immune & InflammationGrade DWeak, conflicting or negative3 primary sources

KPV

Also known as Lys-Pro-Val · α-MSH 11-13 · alpha-MSH C-terminal tripeptide

The C-terminal tripeptide of alpha-MSH, retaining anti-inflammatory activity without pigmentary effects. Preclinical evidence is consistent; human trial evidence is absent.

Overview

KPV is the last three amino acids of alpha-MSH, the same hormone that melanotan compounds mimic. Researchers found that this tiny fragment keeps the anti-inflammatory activity of the parent hormone but loses the pigment-darkening effect, because it no longer binds the pigment receptor. In animal models of colitis and skin inflammation it reduces inflammatory signalling. No controlled human trials have been published.

Research areas

ImmuneInflammatory bowel diseaseDermatologyWound healing

Community-specified data

Community dosage information

Unverified
Community protocol

KPV 10mg

Third-party
01Reconstitution solution
1 mL
02Dose
1 mg
03Syringe units
10 units
04Frequency
7x/week
05Cycle length
90 days
06Bacteriostatic water
1 mL
07Bottle size
10 mg
08Bottles needed
9
Track this schedule

Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.

Dosing reported in the literature

Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.

Protocol as reportedSource
Oral administration in murine DSS and TNBS colitis models, reported in the microgram-per-animal rangeRodent model. No human dose has been established.Dalmasso et al., Gastroenterology 2008
Topical application in murine contact hypersensitivity modelsLuger et al., Annals of the New York Academy of Sciences 1999

Trial status

Preclinical only. No registered human trials.

  1. Preclinical — inflammation models

    Completed1990s–present

    Murine models of colitis, contact dermatitis and systemic inflammation report reduced inflammatory cytokine production and improved histology scores.

  2. Preclinical — transporter characterization

    Completed2008

    PepT1 and HPT1-mediated uptake in human colonic epithelial cells characterized, supporting an oral delivery rationale for intestinal inflammation.

  3. Human trials

    None

    No registered or published controlled human trial.

Reported safety signals

  • No human safety data are published.
  • Preclinical tolerability is reported as good, but rodent tolerability does not establish human safety.
  • The absence of a single registered human trial is the limiting factor on this profile, not any specific safety signal.

Primary sources

3 citations
  1. 01

    PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

    Gastroenterology2008PMID 18054007

  2. 02

    The C-terminal tripeptide of alpha-MSH exerts excellent anti-inflammatory properties

    Annals of the New York Academy of Sciences1999PMID 10604956

  3. 03

    Anti-inflammatory effects of the tripeptide KPV in inflammatory bowel disease models

    Journal of Crohn's and Colitis2014PMID 24499315

Medical disclaimer

This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.

How this profile was built →